ISSN: 1746-0794

Journal Home

Journal Guideline

Future Virology Q4 Unclaimed

Taylor and Francis Ltd. United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Future Virology is a journal indexed in SJR in Virology with an H index of 45. It has a price of 2395 €. It has an SJR impact factor of 0,366 and it has a best quartile of Q4. It has an SJR impact factor of 0,366.

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Virology (Q4)

Price

2395 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

0,366

SJR Impact factor

45

H Index

103

Total Docs (Last Year)

263

Total Docs (3 years)

4880

Total Refs

461

Total Cites (3 years)

242

Citable Docs (3 years)

1.72

Cites/Doc (2 years)

47.38

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Voprosy Virusologii Q4
Zhurnal Mikrobiologii Epidemiologii i Immunobiologii Q4
Journal of Bacteriology and Virology Q4
Infektsionnye Bolezni Q4
Molecular Genetics, Microbiology and Virology Q4

Compare this journals

Aims and Scope

Best articles by citations

The need for concerted action against the cousins of poliovirus

Could boosting the oligoadenylate synthetase-like pathway bring a new era of antiviral therapy?

The early bird gets the worm: benefits and future directions with early antiretroviral therapy initiation in primary HIV infection

Variability in the mutation rates of RNA viruses

CD8 T-cell response to respiratory syncytial virus infection

Infectobesity: the evaluation of adenovirus-36 infection and obesity

India: intellectual property and HIV therapy for the developing world

Immune responses to acute orthopoxvirus infections: what lessons can be learned?

Community-associated methicillin-resistantStaphylococcus aureusand HIV

Could inhibiting IL-8 enhance HBV IFN-a treatment?

Viral oncolysis: an attractive therapeutic for prostate cancer?

Strategies to eliminate HBV infection

SHOW MORE ARTICLES

The road to HIV-1 integrase inhibitors: the case for supporting basic research

Candidate medical countermeasures targeting Ebola virus cell entry

Current and future targets of antiviral therapy in the hepatitis C virus life cycle

Conformational analysis of hepatitis B virus surface antigen mutations among HIV-positive patients diagnosed with occult hepatitis B virus

Albumin-interferon-a in the treatment of chronic hepatitis C

Peginterferon a-2b in the treatment of hepatitis C

Japanese encephalitis: a major public-health debacle

Arboviruses: variations on an ancient theme

Herpes stromal keratitis: erosion of ocular immune privilege by herpes simplex virus

Oncolytic adenovirus research and applications

Phage penetration of eukaryotic cells: practical implications

Phage therapy: unexpected drawbacks to reach hospitals